Cargando…

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

PURPOSE: In patients with hemophilia B, treatment with extended half-life (EHL) recombinant factor IX allows for longer dosing intervals while providing equal or superior bleeding protection compared with standard half-life products. This enables flexible, individualized treatment schedules, which r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Astermark, Jan, Wojciechowski, Piotr, Aballéa, Samuel, Hakimi, Zalmai, Nazir, Jameel, Klamroth, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286734/ https://www.ncbi.nlm.nih.gov/pubmed/34285621 http://dx.doi.org/10.2147/JBM.S312885

Ejemplares similares

Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials
por: Mancuso, Maria Elisa, et al.
Publicado: (2023)

Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B
por: Miguelino, Maricel G, et al.
Publicado: (2014)

Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP
por: von Mackensen, Sylvia, et al.
Publicado: (2018)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
por: Aiello, Andrea, et al.
Publicado: (2020)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
por: López‐Jaime, Francisco José, et al.
Publicado: (2023)

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B
por: Gill, Joan C., et al.
Publicado: (2019)

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
por: Díaz‐Jordán, Bolívar Luis, et al.
Publicado: (2023)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials
por: Klamroth, Robert, et al.
Publicado: (2021)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
por: Tagliaferri, Annarita, et al.
Publicado: (2022)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
por: Simpson, Mindy L, et al.
Publicado: (2019)

Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries
por: Funding, Eva, et al.
Publicado: (2023)

Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
por: Shapiro, Amy, et al.
Publicado: (2020)

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study
por: Pasi, John, et al.
Publicado: (2022)

R&D challenges in FP7
por: Delahaye, P, et al.
Publicado: (2008)

The FP420 R&D Project at the LHC
por: Cox, B.E.
Publicado: (2006)

Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes
por: Liang, Y, et al.
Publicado: (2008)

EU FP7 R&D projects related to the European Strategy
Publicado: (2008)

Run 264, 20b, 26 GeV/c, 26FP, Pressure Bumps in R1
por: Jones, E
Publicado: (1972)

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder
por: Desroziers, Katia, et al.
Publicado: (2013)

Run 376, R1, 26 GeV/c, 26 FP
por: Vos, L
Publicado: (1973)

FP/FORM Versus FP/SAL Within Clinical Practice: An Updated Budget Impact Analysis in Asthma
por: Farrington, Emily, et al.
Publicado: (2016)

16 FP : cuestionario de 16 factores de la personalidad : manual /
Publicado: (2001)

The FP420 Project: The Physics Potential
por: de Roeck, Albert
Publicado: (2008)

The FP420 R&D Project: Higgs and New Physics with forward protons at the LHC
por: Albrow, M.G., et al.
Publicado: (2008)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study
por: Hawken, Natalia, et al.
Publicado: (2016)

PROJECT ADMINISTRATION AGREEMENT KE1926/FP
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2011)

PROJECT ADMINISTRATION AGREEMENT KN 2387 FP
por: THE EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH, CERN, et al.
Publicado: (2014)

Whither α-FP in the diagnosis of hepatocellular carcinoma?
por: Kew, Michael C
Publicado: (2015)

Draft Genome Sequences of Escherichia coli Strains FP2 and FP3, Isolated from the Canada Goose (Branta canadensis)
por: Denny, Allison L., et al.
Publicado: (2018)

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison
por: Hakimi, Zalmai, et al.
Publicado: (2020)

Dissemination of Cost Action FP0905 information by website
por: Migliacci, Fabio, et al.
Publicado: (2011)

Isospin invariant boson models for fp-shell nuclei
por: Van Isacker, P
Publicado: (1994)

Study of fp states in nuclei with high neutron excess
por: Baumann, P, et al.
Publicado: (1988)

Cannot write session to /tmp/vufind_sessions/sess_d53ma03atnrl7n8vf31me3n3kk